BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen GY, Zhu MF, Zheng DL, Bao YT, Wang J, Zhou X, Lou GQ. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2014; 20(25): 8195-8200 [PMID: 25009392 DOI: 10.3748/wjg.v20.i25.8195]
URL: https://www.wjgnet.com/1007-9327/full/v20/i25/8195.htm
Number Citing Articles
1
Michelle Martinot‐Peignoux, Tarik Asselah, Patrick Marcellin. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patientsLiver International 2015; 35(s1): 82 doi: 10.1111/liv.12735
2
Zehong Wang, Xuanxuan Wang, Li Zhou, Shaoyuan Shi, Yongli Hua, Yinong Feng. Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational studyFrontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1489671
3
Feng-Ping Wu, Ying Yang, Mei Li, Yi-Xin Liu, Ya-Ping Li, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Shuang-Suo Dang. Add-on pegylated interferon augments hepatitis B surface antigen clearance <i>vs</i> continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational studyWorld Journal of Gastroenterology 2020; 26(13): 1525-1539 doi: 10.3748/wjg.v26.i13.1525
4
Jin Li, Xiaonan Zhang, Liang Chen, Zhanqing Zhang, Jiming Zhang, Weixia Wang, Min Wu, Bisheng Shi, Xinxin Zhang, Maya Kozlowski, Yunwen Hu, Zhenghong Yuan. Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patientsScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-15594-0
5
Bikrant Bihari Lal, Vikrant Sood, Rajeev Khanna, Dinesh Rawat, Sanjeev Verma, Seema Alam. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B—First study in childrenIndian Journal of Gastroenterology 2018; 37(4): 326 doi: 10.1007/s12664-018-0878-1
6
Michelle Martinot‐Peignoux, Patrick Marcellin. Virological and serological tools to optimize the management of patients with chronic hepatitis BLiver International 2016; 36(S1): 78 doi: 10.1111/liv.12998
7
Roland Kratzer, Benoît Sansas, Karine Lélu, Alexei Evlachev, Doris Schmitt, Nathalie Silvestre, Geneviève Inchauspé, Perrine Martin. A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical modelHuman Vaccines & Immunotherapeutics 2018; 14(6): 1417 doi: 10.1080/21645515.2018.1433970
8
Man-Fung Yuen, Seng-Gee Lim, Robert Plesniak, Keiji Tsuji, Harry L.A. Janssen, Cristina Pojoga, Adrian Gadano, Corneliu P. Popescu, Tatyana Stepanova, Tarik Asselah, Gheorghe Diaconescu, Hyung Joon Yim, Jeong Heo, Ewa Janczewska, Alexander Wong, Nevin Idriz, Michio Imamura, Giuliano Rizzardini, Koichi Takaguchi, Pietro Andreone, Manuela Arbune, Jinlin Hou, Sung Jae Park, Andrei Vata, Jennifer Cremer, Robert Elston, Tamara Lukić, Geoff Quinn, Lauren Maynard, Stuart Kendrick, Helene Plein, Fiona Campbell, Melanie Paff, Dickens Theodore. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionNew England Journal of Medicine 2022; 387(21): 1957 doi: 10.1056/NEJMoa2210027
9
Shuai Wu, Wenfan Luo, Yin Wu, Hongjie Chen, Jie Peng. HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 casesBMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01263-6
10
Xia-Xia Zhang, Min-Ran Li, Hong-Li Xi, Ying Cao, Ren-Wen Zhang, Yu Zhang, Xiao-Yuan Xu. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir TherapyChinese Medical Journal 2016; 129(8): 929 doi: 10.4103/0366-6999.179802
11
Ming‐Yu Zhu, Pei‐Zhan Chen, Jing Li, De‐Min Yu, Dao Huang, Xue‐Juan Zhu, Yue Han, Jie Chen, Wei Huang, Yong‐Yan Chen, Qi‐Ming Gong, Jie‐Hong Jiang, Dong‐Hua Zhang, Yan Zhang, Ji‐Ming Zhang, Xin‐Xin Zhang. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patientsJournal of Medical Virology 2018; 90(4): 721 doi: 10.1002/jmv.25010
12
Jing Huang, Ka Zhang, Wenli Chen, Jinyao Liao, Xiaodan Luo, Ren Chen. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAsScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-13747-9
13
Xiongyue Cao, Qiankun Hu, Wei Xu, Qiang Li, Jiming Zhang, Liang Chen, Yuxian Huang, Xun Qi. Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfaJournal of Viral Hepatitis 2023; 30(4): 310 doi: 10.1111/jvh.13787
14
Somayeh Hadipour, Hasan Afzali. Comparing standard interferon and interferon conjugated with polyethylene glycol for treatment of patients chronically infected with hepatitis B virus infectionInternational Archives of Health Sciences 2017; 4(3): 74 doi: 10.4103/iahs.iahs_14_17
15
Phunchai Charatcharoenwitthaya, Apichat Kaewdech, Teerha Piratvisuth. Controversies in Treating Chronic HBVClinics in Liver Disease 2021; 25(4): 741 doi: 10.1016/j.cld.2021.06.004
16
Yin-Chen Wang, Sien-Sing Yang, Chien-Wei Su, Yuan-Jen Wang, Kuei-Chuan Lee, Teh-Ia Huo, Han-Chieh Lin, Yi-Hsiang Huang. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisScientific Reports 2016; 6(1) doi: 10.1038/srep29605